(6-naphthalen-1-ylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N-methylcarbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: (6-naphthalen-1-ylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N-methylcarbamate
• 化学式: C₂₄H₁₈N₂O₃
• 分子量: 382.4
• InChiKey: BKVUJHQHOJTGTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION<br/>[FR] IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES UTILISES EN TANT QU'AGENTS INHIBITEURS DE LA PROLIFERATION CELLULAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2005075461A1

  公开（公告）日：2005-08-18

  Compounds of the formula (I), wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.

  化合物的公式（I），其中变量基团的定义如内部，并描述了药用盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效果的药物。
• [EN] APOPTOSIS-INDUCING COMPOUNDS<br/>[FR] COMPOSES INDUISANT L'APOPTOSE
  申请人：TRINITY COLLEGE DUBLIN

  公开号：WO2001058904A1

  公开（公告）日：2001-08-16

  The invention relates to a pharmaceutical composition comprising an apoptosis-inducing amount of a compound having general formula (I), wherein: (i) R1 represents an unsubstituted C6 or C10 aryl group; or a C6 aryl group substituted with Me or OMe; (ii) A represents O, S or S partially oxidized to sulfoxide; (iii) the cyclic group labelled F represents an unsubstituted C6 or C10 aryl-fused group or a C5 heteroaryl-fused group (nitrogen as heteroatom) or a benzo-fused system substituted with ethoxycarbonyl function; (iv) and Y represents the group (A) wherein R2 and R3 are independently hydrogen; or methyl; or Y represents the group CH3 or a (CH2)2CH3 group; or an unsubstituted C5 heteroaryl group (nitrogen as heteroatom). The compositions may be used for the treatment of tumours or other cancerous conditions, such as CML (chronic myeloid leukaemia), AML, in AIDS-related lymphomas (such as Karpowski's sarcoma, a sub-cutaneous lymphoma) and used as apoptotic agents in the treatment of cancers generally.

  本发明涉及一种药物组合物，包含一定量的通式（I）化合物，其诱导细胞凋亡的作用，其中：（i）R1代表未取代的C6或C10芳基；或取代有Me或OMe的C6芳基；（ii）A代表O，S或部分氧化为亚砜的S；（iii）标记为F的环状基团代表未取代的C6或C10芳基融合基团或取代有乙氧羰基的苯融合系统或C5杂环芳基融合基团（杂原子为氮）；（iv）Y代表基团（A），其中R2和R3独立地代表氢；或甲基；或Y代表基团CH3或（CH2）2 基团；或未取代的C5杂环芳基（杂原子为氮）。该组合物可用于治疗肿瘤或其他癌症疾病，如慢性髓性白血病（CML）、急性髓性白血病（AML）、艾滋病相关淋巴瘤（如卡波夫斯基肉瘤，一种皮下淋巴瘤）并可作为凋亡剂用于治疗各种癌症。
• APOPTOSIS-INDUCING COMPOUNDS
  申请人：THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

  公开号：EP1255758A1

  公开（公告）日：2002-11-13
• IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION
  申请人：AstraZeneca AB

  公开号：EP1748999A1

  公开（公告）日：2007-02-07
• US6806267B1
  申请人：——

  公开号：US6806267B1

  公开（公告）日：2004-10-19